Linked Life Data

21284801

Source:http://linkedlifedata.com/resource/pubmed/id/21284801

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-4-5
pubmed:abstractText
TB-402 is a novel anticoagulant monoclonal antibody with a prolonged antithrombotic effect resulting from its partial factor (F)VIII inhibition and long half-life. We evaluated the efficacy and safety of a single administration of TB-402 for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1538-7836
pubmed:author
pubmed:copyrightInfo
© 2011 International Society on Thrombosis and Haemostasis.
pubmed:issnType
Electronic
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
664-71
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial.
pubmed:affiliation
Center for Molecular and Vascular Biology, University of Leuven, Belgium. Peter.Verhamme@med.kuleuven.be
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II